As of May 27, 2025, Relmada Therapeutics Inc (RLMD) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Relmada Therapeutics Inc's Forward P/E to Peers
To better understand Relmada Therapeutics Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Relmada Therapeutics Inc (RLMD) | - |
| Catalent Inc (CTLT) | 55.81 |
| Eli Lilly and Co (LLY) | 32.36 |
| Zoetis Inc (ZTS) | 25.38 |
| CorMedix Inc (CRMD) | 15.18 |
| Elanco Animal Health Inc (ELAN) | 14.73 |
Compared to its competitors, Relmada Therapeutics Inc's Forward P/E is difficult to compare due to insufficient data.